ReviewJournal of immunology research2017
Advances in Immunotherapy for Glioblastoma Multiforme.
Review in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.Journal of neuro-oncology · 2024Pooled it
- Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239.Metabolites · 2025Article
- Inhibition of glioblastoma cell proliferation and invasion by the choline-kinase inhibitor JAS239 varies with cell type and hypoxia.bioRxiv : the preprint server for biology · 2024Article
- Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy.Journal of the National Cancer Center · 2023Review
- Correlation of tumor-associated macrophage infiltration in glioblastoma with magnetic resonance imaging characteristics: a retrospective cross-sectional study.Quantitative imaging in medicine and surgery · 2023Article
- Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression.Cancer immunology research · 2023Article
- Novel Derivatives of Tetrahydrobenzo (g) Imidazo[α-1,2] Quinoline Induce Apoptosis Via ROS Production in the Glioblastoma Multiforme Cells, U-87MG.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Glioblastoma Treatment: State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2022Review
- The Roles and Regulation of mBiomedicines · 2022Review
- Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.BMC cancer · 2022Article
- Bibliometric analysis of research on immunogenic cell death in cancer.Frontiers in pharmacology · 2022Article
- Review
- Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.BMC cancer · 2021Article
- Review
- Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma.Science translational medicine · 2021Article
- Review
- Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.Brain pathology (Zurich, Switzerland) · 2021Article
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.